Covidien registers for debt sale to cover $2.3 billion ev3 buyout

Mon, 06/21/2010 - 6:36am
Mass Device

Covidien plc (NYSE:COV) registered for a debt offering with the Securities & Exchange Commission, aiming to drum up some cash to pay for its $2.3 billion acquisition of ev3 Inc (NSDQ:EVVV).

The Mansfield, Mass.-based medical products conglomerate filed shelf registration documents with the SEC indicating its plans to sell an unspecified amount of debt in $1,000 increments.

Earlier this month, Covidien announced its $22.50-per-share bid for Plymouth, Minn.-based ev3, saying it planned to pay for the buyout with cash, debt and a bridge loan. The debt notes will be issued in a series of three offerings, according to a regulatory filing, which did not specify the amount of the notes or their interest rates. Covidien had about $1.72 billion in cash and equivalents as of March 26, according to the filing.

Covidien is also on the hook for $250 million for the pending purchase of oximetry equipment maker Somanetics Corp. (NSDQ:SMTS).

Ev3 makes devices for treating the peripheral vasculature. Today the company announced that the Food & Drug Administration would put a pre-market approval application for one of those devices, the Pipeline brain aneurysm coil, on the fast track for review.




Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.